The Biden administration's last act involved new NIH patent licensing guidelines that impose strict requirements for companies wanting to license NIH discoveries. These rules aim to ensure equitable access but are likely to discourage private-sector investments, which are crucial for transforming research into viable drugs. Historical evidence from the 1990s shows that similar pricing mandates led to a decrease in collaborations with private companies. This shift could jeopardize the commercialization of NIH-funded research and ultimately limit healthcare innovations stemming from public investments.
The historical and economic data is clear. Without private-sector investments, the relatively smaller NIH-funded lab work will be squandered on discoveries that will never result in real-world drug treatments.
The NIH's new patent licensing guidelines require companies to ensure 'affordability, availability, acceptability, and sustainability' of products, shifting the NIH into a role as a price regulator.
NIH's 'reasonable pricing' mandate in the 1990s caused a significant drop in private collaborations, proving such regulations detrimental to the innovation ecosystem.
When the price-control mandate was repealed, collaboration agreements rebounded by over 400%, illustrating the negative impact of imposed pricing on private-sector partnerships.
Collection
[
|
...
]